This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Mary Sano, PhD; Karen Bell, MD; Lucien Cote, MD; George Dooneief, MD; Arlene Lawton, RN; Louise Legler, MA; Karen Marder, MD; Ali Naini, PhD; Yaakov Stern, PhD; Richard Mayeux, MD

Arch Neurol. 1992;49(11):1137-1141.

Abstract
• Acetyl levocarnitine hydrochloride has been reported to retard dementia in patients with Alzheimer's disease. In a double-blind, parallel design, placebo-controlled pilot study of 30 mild to moderately demented patients with probable Alzheimer's disease, tests of memory, attention, language, visuospatial, and constructional abilities were administered, and the level of acetyl levocarnitine was measured in the cerebrospinal fluid. Patients were then randomly assigned to receive acetyl levocarnitine hydrochloride (2.5 g/d for 3 months followed by 3 g/d for 3 months) or placebo. After 6 months, the acetyl levocarnitine group demonstrated significantly less deterioration in timed cancellation tasks and Digit Span (forward) and a trend toward less deterioration in a timed verbal fluency task. No differences were found in any other neuropsychological test results. A subgroup with the lowest baseline scores, receiving acetyl levocarnitine, had significantly less deterioration on the verbal memory test and a significant increase in cerebrospinal fluid acetyl levocarnitine levels compared with those receiving placebo. These results suggest that acetyl levocarnitine may retard the deterioration in some cognitive areas in patients with Alzheimer's disease and stress the need for a larger study of this drug.

Author Affiliations
From the Departments of Neurology (Drs Sano, Bell, Cote, Dooneief, Marder, Naini, Stern, and Mayeux and Mss Lawton and Legler) and Psychiatry (Drs Stern and Mayeux), Columbia University, College of Physicians and Surgeons; The New York State Psychiatric Institute Memory Disorders Clinic, New York (Drs Sano, Bell, Dooneief, Marder, Stern, and Mayeux); and the Center for Alzheimer's Disease Research (Drs Sano, Marder, Stern, and Mayeux), New York. Dr Sano is a Herbert Irving Assistant Professor in the Department of Neurology.

Footnotes
Accepted for publication May 12, 1992.

Reprint requests to the Neurological Institute, 710 W 168th St, New York, NY 10032 (Dr Sano).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effectiveness of Nutritional Supplements on Cognitive Functioning in Elderly Persons: A Systematic Review
Manders et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2004;59:M1041-M1049.
ABSTRACT | FULL TEXT  

A 1-year controlled trial of acetyl-L-carnitine in early-onset AD
Barrett and Thal
Neurology 2001;56:425-425.
FULL TEXT  

Treatment of Alzheimer's Disease
Mayeux and Sano
NEJM 1999;341:1670-1679.
FULL TEXT  

The treatment of Alzheimer's disease
Allen and Burns
J Psychopharmacol 1995;9:43-56.